About us
Lys Therapeutics, first-in-class biotherapies against neurological diseases
Dr. Thibault HONEGGER, PhD
Co-founder, member of the Strategic Committee
Philippe DUJARDIN
Co-founder, Chief Financial Officer, member of the Strategic Committee
Dr. Manuel BLANC, PhD, MBA
Co-founder, Chief Executive Officer, President of the Strategic Committee
Dr. François FOSSIEZ, PhD
Head of CMC
Dr. Flavie LESEPT, PhD
Project Manager, Preclinical R&D
Pr. Denis VIVIEN, PhD, PU-PH
Head of Science, President of the Scientific Advisory Board
Co-founder, CEO, President of the Strategic Committee
Co-founder, member of the Strategic Committee
Co-founder, member of the Strategic Committee
President of the Scientific Advisory Board – acting CSO
Head of CMC
Project Manager, Preclinical R&D
Head of IT and data protection
President of the SAB: Pr. Denis Vivien (PhD, PU-PH), France, co-inventor of Glunomab & expert of tPA, head of the Research Institute “Blood and Brain @ Caen-Normandie”
Dr. Richard Macrez (MD, PhD), France, co-inventor of Glunomab, assistant professor and emergency physician, head of Emergency Unit at Caen-Normandie Hospital
Dr. Désiré COLLEN (MD, PhD), Belgium, inventor of rtPA (alteplase) still the most effective drug for thrombolytic therapy of acute myocardial infarction and ischemic stroke
Pr. Diederik DIPPEL (MD, PhD), the Netherlands, neurologist, co-director of the Erasmus University MC Stroke Center
Pr. Yannick BÉJOT (MD, PhD), France, neurologist, head of Neurology at Dijon-Bourgogne hospital
Pr. Joan MONTANER (MD, PhD), Spain, neurologist, head of Neurovascular Research at the Vall d’Hebron Research Institute
Via BB@C Institute: Pr. Martin Dichgans (MD, PhD), Germany, neurologist, Director of the Institute of Stroke and Dementia Research (Medical Center of the University of Munich), head of the World Stroke Organization
Via BB@C Institute: Pr. Eng Lo (MD, PhD), USA, neurologist, Professor of Neurology and Radiology, Harvard Medical School, and Research Staff, Massachusetts General Hospital
An outstanding scientific background
Glunomab / Glunozumab®: a monoclonal antibody counteracting the strong toxicity triggered by the interaction
of an endogenous protease, tissue plasminogen activator (tPA) with NMDA receptors (NMDAr)
In the pathophysiology of neurological diseases such as stroke, multiple sclerosis, Parkinson’s disease as well as many other neurodegenerative disorders, one protease called tissue plasminogen activator (tPA) is triggering off-target toxicity via the binding to NMDA receptors (NMDAr) present on vascular endothelial cells and neurons, leading to its consequent hyperactivation and causing deleterious increase of the permeability of the blood brain barrier, as well as strong neuroinflammation and excitotoxicity.
By blocking the tPA-NMDAr interaction, Glunomab / Glunozumab® counteracts this tPA-dependent strong toxicity, without interfering with physiological NMDAr functioning.
A systemic drug treatment for CNS pathologies:
A very high specificity:
A fully characterized mechanism of action:
Therapeutic effects on blood brain barrier permeability and associated neuroinflammation and excitotoxicity
Submitted 2022
We don’t have open positions at the moment, stay tuned!